Acquired resistance to aromatase inhibitors: where we stand!

Area of Science:

• Oncology
• Endocrinology
• Molecular Biology

Background:

• Aromatase inhibitors (AIs) are a primary treatment for postmenopausal ER+ breast cancer.
• AIs function by inhibiting aromatase, thereby blocking estrogen biosynthesis and halting tumor progression.
• Despite therapeutic success, acquired resistance to AIs can lead to tumor relapse.

Purpose of the Study:

• To investigate the biological mechanisms underlying acquired endocrine resistance to aromatase inhibitors in breast cancer.
• To explore the role of estrogen receptor (ER) behavior changes, PI3K/AKT pathway, and other signaling pathways in resistance.
• To understand the lack of cross-resistance among different AIs and identify strategies to overcome acquired resistance.

Main Methods:

• Review of current literature on aromatase inhibitors and endocrine resistance in breast cancer.
• Analysis of signaling pathways implicated in AI resistance, including PI3K/AKT and androgen receptor (AR) pathways.
• Examination of biological mechanisms such as apoptosis, autophagy, and cell cycle modulation.

Main Results:

• Acquired resistance to AIs is associated with altered ER behavior and enhanced PI3K/AKT signaling.
• Apoptosis, autophagy, cell cycle modulation, and AR activation are implicated in resistance mechanisms.
• Clinical data suggest a lack of cross-resistance among AIs, though underlying reasons require further investigation.

Conclusions:

• Understanding the diverse mechanisms of endocrine resistance to specific AIs is essential.
• Further research is needed to develop novel strategies to overcome acquired resistance and improve breast cancer treatment outcomes.
• Investigating AI resistance mechanisms can guide the development of more effective therapies for ER+ breast cancer.